Abstract 1054P
Background
Chimeric antigen receptor (CAR) T-cell therapy holds great promise for the treatment of solid tumors; however, how to avoid or minimize the “on-target off-tumor” effect of CAR-T therapy remains a major issue, we developed a P329G (PG) modular and switchable CAR technology, in which CAR-T cells bind tumor antigens indirectly via an Fc-silent tumor-targeting human antibody(Ab) containing the PG mutation as an adapter molecule, whose activity is controllable by the PG Ab. Here, we report the first-in-human clinical results of a CLDN18.2-targeting PG CAR-T product (IBI345) for the treatment of CLDN18.2+ solid tumors.
Methods
In this phase 1a study, patients (pts) with CLDN18.2+ advanced solid tumor received an infusion of IBI345 consisting of one dose of PG CAR-T cells at escalating doses of 50, 250×106 cells plus ≥ 1 dose of CLDN18.2-targeting PG Ab at a fixed dose of 1mg/kg Q3W after lymphodepletion preconditioning. The objectives include safety and tolerability, pharmacokinetics and preliminary efficacy (per RECIST 1.1) of IBI345.
Results
As of Apr 7, 2023, 5 pts were treated with IBI345. All 5 pts experienced TRAEs, and grade ≥ 3 TRAE were neutrophil count decreased (n=2) and decreased appetite (n=1). No CRS, ICANS or treatment-related deaths occurred. For 4 efficacy-evaluable pts (Table), 1 EGJC pt achieved PR and 2 pts (1 GC, 1 PC) achieved SD. CAR-T expansion and persistence were detected in all pts, with a median peak of 1,840 copies/μg gDNA (1,500-4,020), a median time to peak of 16 days (9-20), and a median persistence of 45 days (35-127). Table: 1054P
Overview of clinical and biomarker results for each individual patient
IBI345 | Patient | CLDN 18.2 expression | Age (years) | Gender | Tumor Type | Previous lines | Best overall response |
IBI345 PG IgG 1mg/kg + PG CAR-T cells 50*10ˆ6 | PT01 | 1+, 12%; 2+,3%; 3+, 0% | 69 | Male | Esophagogastric junction cancer (EGJC) | 2 | Partial response |
IBI345 PG IgG 1mg/kg + PG CAR-T cells 250*10ˆ6 | PT02 | 1+, 1%; 2+,0%; 3+, 0% | 64 | Male | Gastric cancer (GC) | 2 | Stable disease |
PT03 | 1+, 0%; 2+, 5%; 3+, 90% | 60 | Male | Pancreatic cancer (PC) | 2 | Stable disease | |
PT04 | 1+, 0%; 2+, 0%; 3+, 100% | 68 | Female | Pancreatic cancer (PC) | 3 | Progressive disease |
Conclusions
IBI345 demonstrated a manageable safety profile and preliminary efficacy in patients with CLDN18.2+ advanced solid tumors. To realize the full potential of this modular CAR-T cell product, the dose and regimen of the P329G Ab and CAR-T cells requires further exploration.
Clinical trial identification
NCT05199519.
Editorial acknowledgement
Weichang Chen is the corresponding author.
Legal entity responsible for the study
Innovent Cells Pharmaceuticals.
Funding
Innovent Cells Pharmaceuticals.
Disclosure
M. Li: Other, Personal, Affiliate, EMPLOYMENT: Innovent Cells Pharmaceuticals. H. Wei: Other, Personal, Other, EMPLOYMENT: Innovent Cells Pharmaceuticals. L. Sun: Other, Personal, Other, EMPLOYMENT: Innovent Cells Pharmaceuticals. Q. Xie: Other, Personal, Other, EMPLOYMENT: Innovent Biologics, Inc.. E. Lin: Other, Personal, Other, EMPLOYMENT: Innovent Biologics, Inc.. D. Xu: Other, Personal, Other, EMPLOYMENT: Innovent Cells Pharmaceuticals. J. Tian: Other, Personal, Other, EMPLOYMENT: Innovent Cells Pharmaceuticals. J. Chen: Other, Personal, Other, EMPLOYMENT: Innovent Cells Pharmaceuticals. W. Lu: Other, Personal, Other, EMPLOYMENT: Innovent Cells Pharmaceuticals. N. Gao: Other, Personal, Other, EMPLOYMENT: Innovent Biologics, Inc.. L. Chen: Other, Personal, Other, EMPLOYMENT: Innovent Biologics, Inc.. J. Duo: Other, Personal, Other, EMPLOYMENT: Innovent Cells Pharmaceuticals. L. Ye: Other, Personal, Other, EMPLOYMENT: Innovent Cells Pharmaceuticals. T. Cheng: Other, Personal, Other, EMPLOYMENT: Innovent Cells Pharmaceuticals. Y. Sui: Other, Personal, Other, EMPLOYMENT: Innovent Cells Pharmaceuticals. C. Klein: Other, Personal, Other, EMPLOYMENT: Roche Innovation Center Zurich. All other authors have declared no conflicts of interest.
Resources from the same session
1037P - Phase I dose-escalation trial with tumor-targeted interleukin-12 (IL12-L19L19) in patients with solid tumors
Presenter: Nicolas Mach
Session: Poster session 19
1039P - First-in-human phase I study of givastomig, a novel Claudin 18.2/4-1BB bispecific antibody in advanced solid tumors
Presenter: Geoffrey Ku
Session: Poster session 19
1040P - Phase I study of IL-8 inhibitor AMY109 plus atezolizumab (atezo) in patients (pts) with advanced solid tumours
Presenter: Yasutoshi Kuboki
Session: Poster session 19
1041P - Phase I open-label, dose escalation and expansion study of YH003, an anti-CD40 agonist monoclonal antibody in combination with toripalimab in patients (pts) with advanced solid tumours
Presenter: Ben Markman
Session: Poster session 19
1042P - INSIGHT 003 evaluating feasibility of eftilagimod alpha (soluble LAG-3) combined with first-line chemo-immunotherapy in metastatic non-small cell lung cancer (NSCLC) adenocarcinomas
Presenter: Akin Atmaca
Session: Poster session 19
1043P - First-in-human study of TU2218, TGFβRI and VEGFR2 dual inhibitor in patients with advanced solid tumors
Presenter: Do-Youn Oh
Session: Poster session 19
1044P - A phase Ia first-in-human study of JS007, a novel anti-CTLA-4 monoclonal antibody, in patients with advanced solid tumors
Presenter: Jun Zhang
Session: Poster session 19
1045P - Safety and preliminary clinical activity of JNJ-78306358 (JNJ-358), an HLA-G and CD3 bispecific antibody, for the treatment of advanced stage solid tumor
Presenter: Ravit Geva
Session: Poster session 19
1046P - Phase I/II open-label study on an anti-GPC3 T cell engager, SAR444200, in patients with advanced solid tumors: Preliminary dose escalation results
Presenter: Jung Yong Hong
Session: Poster session 19